查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806136

動物用藥品市場按產品類型、動物種類、給藥途徑、疾病類型、最終用戶和分銷管道分類－2025-2030 年全球預測

Animal Pharmaceuticals Market by Product Type, Species, Route of Administration, Disease Type, End User, Distribution Channels - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2024 年動物用藥品市場價值將達到 418.9 億美元，到 2025 年將成長至 457.4 億美元，複合年成長率為 9.29%，到 2030 年將達到 714 億美元。

主要市場統計數據
基準年2024年 418.9億美元
預計2025年 457.4億美元
預測年份 2030 714億美元
複合年成長率（%） 9.29%

在全球健康需求和技術進步的背景下，為動物用藥品策略成長奠定基礎

全球動物用藥品產業正處於關鍵的十字路口，消費者行為的轉變、疾病光譜的演變以及技術突破共同重塑傳統的市場動態。同時，伴侶動物照護也持續受益於寵物擁有量的增加和預防性治療支出的增加。此外，人們對通用感染疾病傳播的認知不斷提高，這促使相關人員加快疫苗和診斷方法的研究，以保護動物和人類的健康。

了解推動全球獸醫市場動物用藥品開發和交付模式轉移的因素

隨著精準醫療、數位診斷和新型生技藥品重新定義治療模式，獸醫醫療保健領域正在經歷變革時期。包括次單位疫苗和減毒疫苗在內的先進疫苗平台展現出卓越的安全性和免疫抗原性，促使製造商重新評估傳統方法。同時，遠端醫療與基於感測器的監測技術的融合，實現了即時疾病監測，促進了早期療育並降低了整體治療成本。

評估2025年美國關稅政策對動物用藥品市場供應、定價壓力和策略調整的多層影響

2025年，美國將對進口的關鍵動物用藥品分階段徵收關稅，這將給整個供應鏈帶來新的成本壓力，並迫使製造商重新評估其活性藥物​​原料藥籌資策略。抗生素、荷爾蒙和疫苗佐劑的供應商正面臨利潤壓縮，迫使相關人員探索其他貿易夥伴關係和近岸外包選項。因此，國內製造能力正在透過產能投資和本地製造協議進行擴張，以緩解關稅造成的價格波動。

探索跨產品、物種、管理、疾病、最終用戶和管道維度的策略性細分機會

詳細的細分分析揭示了產品系列中的重要差異，麻醉劑和消炎藥等傳統類別與快速成長的生物疫苗和標靶驅蟲藥並存。抗生素仍發揮重要作用，但其種類日益多樣化，反映了治療應用的細微差別，包括Fluoroquinolones、大環內酯類、青黴素類、磺胺類藥物和四環黴素。同時，驅蟲藥策略正在不斷發展，以平衡廣譜和專一性外寄生蟲殺蟲劑之間的療效，去活化疫苗、減毒活病毒疫苗和次單位疫苗則在安全性、成本和免疫反應方面展開競爭。

繪製美洲、歐洲、中東和非洲地區以及亞太地區的區域動態，以擴大市場並客製化動物用藥品解決方案

尤其是在北美，大規模畜牧養殖與成熟的伴侶動物市場共存。重要的是，區塊鏈支援的可追溯性和整合低溫運輸物流等供應鏈創新正在提高透明度、減少腐敗，並進一步提升市場效率。在拉丁美洲，酪農和牛肉產業的擴張正推動人們對經濟高效的非專利藥和社區疫苗接種舉措的興趣。

分析動物保健產業的領先創新者，了解競爭定位、合作趨勢和通路顛覆策略

動物用藥品市場的領導地位體現在由行業巨頭、專業化的中型企業和敏捷的生物技術公司組成的生態系統中。老字型大小企業正利用深厚的研發開發平臺，開發下一代疫苗、單株抗體和長效注射劑，以應對諸如抗生素抗藥性和跨物種通用感染疾病威脅等緊迫挑戰。同時，中型企業則專注於利潤率較高的領域，例如馬匹治療、精準驅蟲藥和客製化營養補充劑，從而開拓利基市場。

產業領導者需要應對複雜的監管環境、利用技術進步並最佳化價值鏈的策略要務

產業領導者必須優先將數位健康工具整合到其全球商業化策略中。對遠端醫療平台、感測器診斷和數據分析解決方案的投資，不僅可以改善治療效果，還能創造差異化的服務，加深客戶參與。此外，與生物技術新興企業建立策略合作夥伴關係可以加速其獲得基因編輯和合成生物學等創新平台的途徑，使他們能夠持續將顛覆性療法引入其產品組合。

概述對全球動物用藥品狀況進行全面分析所採用的嚴格定性和定量方法

本分析基於嚴謹的調查方法，結合了定性和定量分析。主要研究包括對動物用藥品製造商的高階主管、監管專家、供應鏈經理和學術研究人員進行深入訪談。這些訪談提供了新興趨勢、策略重點和營運挑戰的第一手觀點。

綜合關鍵見解，為不斷發展的全球動物用藥品生態系統中的相關人員提供指導

在本執行摘要中，我們探討了重塑動物用藥品產業的複雜因素，從不斷變化的消費者需求和監管改革，到技術突破和地緣政治逆風。這些因素的交織凸顯了相關人員採取靈活策略、利用創新並增強供應鏈韌性的必要性。市場領導者必須追求差異化的價值提案，同時對貿易政策和疾病模式演變所帶來的成本壓力保持警覺。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 單株抗體療法在防治牲畜疾病的應用
  • 擴大採用行動獸醫遠端醫療平台進行遠端動物健康管理
  • 開發抗生素替代品，例如噬菌體療法，以對抗牲畜的抗生素抗藥性
  • 為簡化馬匹和牛的疫苗接種計劃，對聯合疫苗通訊協定的需求不斷成長
  • 實施基於區塊鏈的可追溯系統以追蹤動物醫藥分銷和使用合規性
  • 基於人工智慧生物標記的精準給藥技術的發展，最佳化了家禽的抗菌劑量
  • 擴大數位診斷，利用照護現場分子檢測技術，早期檢測伴侶動物的寄生蟲

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章動物用藥品市場（依產品類型）

  • 麻醉劑
  • 抗發炎藥物
  • 抗生素
    • Fluoroquinolones
    • 大環內酯類
    • 青黴素
    • 磺胺類藥物
    • 四環黴素
  • 荷爾蒙和生長調節劑
  • 殺寄生蟲劑
    • 驅蟲藥
    • 殺外寄生蟲劑
  • 疫苗
    • 去活化疫苗
    • 減毒活疫苗
    • 次單位疫苗

第9章動物用藥品動物類型）

  • 水生動物
  • 鳥
  • 伴侶動物
    • 貓
    • 狗
    • 馬
  • 家畜
    • 牛
    • 家禽
    • 綿羊和山羊
    • 豬
  • 野生動物

第10章動物用藥品市場按管理途徑

  • 口服
    • 膠囊
    • 液體溶液
    • 粉末
    • 藥片
  • 注射藥物
  • 外用
    • 奶油
    • 軟膏
    • 噴

第11章動物用藥品市場（依疾病類型）

  • 感染疾病
    • 細菌感染疾病
    • 黴菌感染疾病
    • 寄生蟲感染
    • 病毒感染
  • 非傳染性疾病
    • 發炎性疾病
    • 代謝紊亂
    • 營養缺乏
    • 生殖障礙

第12章動物用藥品市場（依最終用戶）

  • 政府和公共衛生機構
  • 牲畜和家禽養殖場
  • 寵物飼主
  • 研究機構
  • 獸醫診所和醫院

第13章動物用藥品市場（依通路）

  • 線下藥局
  • 網路藥局

第 14 章：美洲動物用藥品市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 15 章：歐洲、中東和非洲動物用藥品市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 16 章：亞太動物用藥品市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Aurora Pharmaceutical, Inc.
    • Biogenesis Bago SA
    • Biovac Ltd.
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • China Animal Husbandry Industry Co., Ltd.
    • Dechra Pharmaceuticals PLC
    • ECO Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Hester Biosciences Limited
    • Huvepharma, Inc.
    • Indian Immunologicals Ltd.
    • Intas Pharmaceuticals Ltd.
    • Laboratorio Drag Pharma Chile Invetec SA
    • Merck & Co., Inc.
    • Neogen Corporation
    • Nippon Zenyaku Kogyo Co., Ltd.
    • Norbrook Group
    • Orion Corporation
    • PetIQ, LLC
    • Phibro Animal Health Corporation
    • Teknofarma Srl
    • Veterinary Pharmaceutical Solutions
    • Vetoquinol Group
    • Vetpharma Animal Health SL by Insud Pharma SLU
    • Virbac SA
    • Zendal Group
    • Zoetis Inc.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-434CCDA05128

The Animal Pharmaceuticals Market was valued at USD 41.89 billion in 2024 and is projected to grow to USD 45.74 billion in 2025, with a CAGR of 9.29%, reaching USD 71.40 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 41.89 billion
Estimated Year [2025] USD 45.74 billion
Forecast Year [2030] USD 71.40 billion
CAGR (%) 9.29%

Laying the Groundwork for Strategic Growth in Animal Pharmaceuticals Amidst Evolving Global Health Demands and Technological Advancements

The global animal pharmaceuticals sector stands at a pivotal juncture as shifting consumer behaviors, evolving disease profiles, and technological breakthroughs converge to reshape traditional market dynamics. Intensifying demand for high-quality protein sources in emerging economies is driving unprecedented investment in livestock health solutions, while companion animal care continues to benefit from rising pet ownership and increasing expenditures on preventive therapies. Furthermore, heightened awareness of zoonotic disease transmission is compelling stakeholders to accelerate research into vaccines and diagnostics that protect both animal and human health.

Amid these trends, regulatory agencies worldwide are streamlining approval pathways for innovative biologics, antimicrobial agents, and point-of-care diagnostics. Public-private partnerships are emerging to combat antimicrobial resistance, while venture capital initiatives are fueling startups to explore gene editing, precision dosing, and digital health platforms. These developments underscore the importance of a multi-faceted strategy that balances the need for rapid product development with stringent safety and efficacy standards.

Accordingly, industry leaders must ground their growth plans in robust market intelligence that captures complex value chains, evolving regulatory frameworks, and shifting epidemiological patterns. By aligning R&D pipelines with emerging customer needs and leveraging cross-sector collaborations, stakeholders can unlock sustainable growth and build resilience against future disruptions.

Uncovering the Forces Driving a Paradigm Shift in Animal Health Treatment Development and Delivery Across Global Veterinary Markets

The animal health landscape is witnessing transformative shifts as precision medicine, digital diagnostics, and novel biologics redefine treatment paradigms. Advanced vaccine platforms, including subunit and attenuated modalities, are demonstrating superior safety profiles and immunogenicity, driving manufacturers to re-evaluate traditional approaches. Meanwhile, the integration of telemedicine and sensor-based monitoring is enabling real-time disease surveillance, facilitating earlier intervention and reducing overall treatment costs.

Moreover, growing concerns around antimicrobial resistance have accelerated interest in alternative therapies such as phage therapy, probiotics, and host-directed immunomodulators. Companies are forging alliances with academic institutions to fast-track these innovations through collaborative research and pooled expertise. In parallel, artificial intelligence and machine learning models are being deployed to optimize dosage regimens and forecast disease outbreaks based on environmental and genetic risk factors.

Consequently, organizations that embrace these disruptive technologies while maintaining a strong focus on regulatory compliance and cost-effectiveness will be best positioned to capture emerging market segments. Building flexible supply networks and investing in agile manufacturing processes will further enable rapid scale-up of production, ensuring timely delivery of next-generation therapies to meet evolving veterinary needs.

Assessing the Layered Effects of 2025 US Tariff Policies on Supply, Pricing Pressure, and Strategic Realignment in the Animal Pharmaceuticals Market

In 2025, the imposition of layered US tariffs on key animal pharmaceutical imports has introduced new cost pressures throughout the supply chain, compelling manufacturers to reassess sourcing strategies for active pharmaceutical ingredients. Suppliers of antibiotics, hormones, and vaccine adjuvants have experienced margin compression, prompting stakeholders to explore alternative trade partnerships and near-shoring options. As a result, domestic production capabilities are being expanded through capacity investments and localized manufacturing agreements to mitigate tariff-induced price volatility.

Furthermore, higher import duties have led to downstream pricing adjustments that influence end-user purchasing behavior, with veterinary clinics and farms increasingly seeking value-based contracts and bundled service offerings. This shift is accelerating the adoption of generic formulations and biosimilars in regions where cost sensitivity remains high. At the same time, premium markets with strong veterinary infrastructure continue to exhibit willingness to pay for innovative biologics and advanced diagnostics.

Accordingly, agile supply chain management and proactive regulatory engagement are paramount. Organizations that secure diversified raw material sources, negotiate long-term procurement agreements, and establish in-country fill-finish capabilities will build resilience against future trade disruptions. Embracing digital supply chain visibility tools and advanced analytics will further empower decision-makers to respond swiftly to shifting tariff landscapes and maintain competitive pricing.

Delving into Product, Species, Administration, Disease, End User, and Channel Dimensions to Reveal Strategic Segmentation Opportunities

Deep segmentation analysis reveals critical differentiation within the product portfolio, where traditional categories such as anesthetics and anti-inflammatory medications coexist with fast-growing biologic vaccines and targeted parasiticides. Antibiotics maintain a prominent role but are increasingly stratified across fluoroquinolones, macrolides, penicillins, sulfonamides, and tetracyclines, reflecting nuanced therapeutic applications. At the same time, parasiticide strategies are evolving to balance efficacy between broad-spectrum anthelmintics and specialized ectoparasiticides, while inactivated vaccines, live attenuated vaccines, and subunit vaccines compete on the basis of safety, cost, and immune response.

Equally important is the species dimension, where treatments for aquatic animals, birds, companion animals such as cats, dogs, and horses, livestock including cattle, poultry, sheep and goats, and swine, as well as wild animal care, present unique pharmacological and delivery challenges. Route of administration further refines market opportunities, as oral solutions in capsules, liquids, powders, and tablets offer convenience but face bioavailability constraints, while parenteral interventions dominate acute care and topical formulations in creams, ointments, and sprays address localized conditions. Disease type segmentation divides interventions between infectious diseases, encompassing bacterial, fungal, parasitic, and viral infections, and non-infectious disorders that range from inflammatory diseases to metabolic, nutritional, and reproductive disorders. End-user profiles complete the landscape, where government and public health bodies, livestock and poultry farms, pet owners, research institutions, and veterinary clinics and hospitals each demonstrate distinct procurement criteria. Finally, the channel dimension highlights the rising influence of online pharmacies alongside established offline pharmacy networks, signaling a shift in distribution strategies.

Mapping Regional Dynamics in Americas, EMEA, and Asia-Pacific to Guide Market Expansion and Tailored Veterinary Health Solutions

Regional dynamics in the Americas continue to be shaped by robust research infrastructure, well-defined regulatory pathways, and high per-animal expenditure, particularly in North America where large-scale livestock operations and sophisticated companion animal markets coexist. Importantly, supply chain innovations such as blockchain-enabled traceability and integrated cold-chain logistics are enhancing transparency and reducing spoilage, further bolstering market efficiency. In Latin America, expanding dairy and beef industries are driving interest in cost-effective generic therapeutics and community vaccination initiatives.

Across Europe, Middle East, and Africa, heterogeneous regulatory frameworks present both challenges and opportunities. EU member states emphasize stringent safety and environmental standards, spurring investment in next-generation biologics and antimicrobial stewardship programs. Meanwhile, Middle Eastern markets are witnessing an uptick in private veterinary services and demand for premium companion animal products. In Africa, emerging economies are prioritizing zoonotic disease control through public health campaigns and donor-funded vaccine distribution, highlighting the need for low-cost, thermostable formulations.

Asia-Pacific stands out for its dual landscape of rapidly modernizing production hubs and diverse disease burdens. Countries with advanced manufacturing capacity, such as Japan and South Korea, continue to lead innovation in precision biologics, while China and India are scaling up generic production to serve domestic and export markets. Southeast Asian nations are increasingly focused on aquaculture health solutions, reflecting the region's significant contribution to global fish protein supply. These varied regional profiles underscore the importance of tailored market entry and product strategies.

Profiling Leading Animal Health Innovators to Understand Competitive Positioning, Collaborative Trends, and Pipeline Disruption Strategies

Market leadership in animal pharmaceuticals is characterized by an ecosystem of industry giants, specialized mid-tier players, and agile biotechnology firms. Established corporations are leveraging their deep R&D pipelines to advance next-generation vaccines, monoclonal antibodies, and long-acting injectables that address pressing challenges such as antimicrobial resistance and cross-species zoonotic threats. Meanwhile, mid-sized companies are carving out niche positions by focusing on high-margin segments such as equine therapeutics, precision parasiticides, and bespoke nutritional supplements.

Collaborative partnerships are reshaping the competitive landscape, as alliances between multinational firms and academic spin-offs accelerate translational research. Licensing agreements for proprietary adjuvants and novel delivery technologies are becoming increasingly common, enabling smaller innovators to scale their solutions through established global networks. In addition, strategic M&A activity highlights a trend toward consolidating complementary capabilities, with acquirers seeking to bolster biologics platforms and digital health offerings. These moves are redefining traditional market hierarchies and setting new benchmarks for value creation.

Strategic Imperatives for Industry Leaders to Navigate Regulatory Complexity, Leverage Technological Advances, and Optimize Value Chains

Industry leaders must prioritize the integration of digital health tools into their global commercialization strategies. Investing in telemedicine platforms, sensor-enabled diagnostics, and data analytics solutions will not only enhance treatment outcomes but also create differentiated service offerings that deepen customer engagement. Furthermore, forging strategic alliances with biotechnology startups can accelerate access to innovative platforms such as gene editing and synthetic biology, ensuring a continuous flow of disruptive therapies into the portfolio.

Regulatory engagement should be elevated from a compliance function to a proactive strategic capability. By participating in policy dialogues, contributing to antimicrobial stewardship guidelines, and advocating for harmonized approval pathways, organizations can shape favorable environments for advanced biologics and novel modalities. Finally, building supply chain resilience through diversified sourcing, in-country manufacturing partnerships, and digital traceability systems will safeguard against future trade disruptions and strengthen market responsiveness.

Outlining Rigorous Qualitative and Quantitative Approaches Underpinning Comprehensive Analysis of the Global Animal Pharmaceuticals Landscape

This analysis is founded on a rigorous research methodology that integrates both qualitative and quantitative approaches. Primary research included in-depth interviews with senior executives at veterinary pharmaceutical manufacturers, regulatory experts, supply chain managers, and academic researchers. These conversations provided firsthand perspectives on emerging trends, strategic priorities, and operational challenges.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, patent databases, and industry publications. Market dynamics were further validated through proprietary data sets and trade statistics, while competitive landscapes were mapped using detailed product registries and company disclosures. All data points underwent cross-verification to ensure accuracy and relevance, and insights were synthesized through collaborative workshops with subject-matter experts. This robust methodology underpins the credibility and depth of our findings.

Synthesizing Critical Findings to Chart a Path Forward for Stakeholders in the Evolving Global Veterinary Pharmaceuticals Ecosystem

Throughout this executive summary, we have navigated the intricate forces reshaping the animal pharmaceuticals industry, from shifting consumer demands and regulatory reforms to technological breakthroughs and geopolitical headwinds. The convergence of these factors underscores the necessity for stakeholders to adopt agile strategies, harness emerging innovations, and strengthen supply chain resilience. As market leaders pursue differentiated value propositions, they must remain vigilant to cost pressures introduced by trade policies and evolving disease patterns.

Looking ahead, sustained growth will depend on the ability to balance investment across core segments such as antibiotics, vaccines, and parasiticides while exploring frontier areas including precision biologics, digital health, and alternative therapeutics. By embedding a culture of continuous innovation and proactive collaboration, organizations can position themselves to meet the complex health needs of diverse animal populations and drive sustainable value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Use of monoclonal antibody therapies for livestock disease prevention and treatment
  • 5.2. Increasing adoption of mobile veterinary telemedicine platforms for remote animal health management
  • 5.3. Development of antibiotic alternatives such as bacteriophage therapies to combat antimicrobial resistance in farm animals
  • 5.4. Rising demand for combination vaccine protocols to streamline immunization schedules in equine and cattle herds
  • 5.5. Implementation of blockchain-based traceability systems for tracking veterinary drug distribution and usage compliance
  • 5.6. Growth of precision dosing technologies using ai-enabled biomarkers for optimized antimicrobial administration in poultry
  • 5.7. Expansion of parasitic digital diagnostics using point-of-care molecular assays for early detection in companion animals

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Animal Pharmaceuticals Market, by Product Type

  • 8.1. Introduction
  • 8.2. Anesthetics
  • 8.3. Anti-Inflammatory Medications
  • 8.4. Antibiotics
    • 8.4.1. Fluoroquinolones
    • 8.4.2. Macrolides
    • 8.4.3. Penicillins
    • 8.4.4. Sulfonamides
    • 8.4.5. Tetracyclines
  • 8.5. Hormones & Growth Regulators
  • 8.6. Parasiticides
    • 8.6.1. Anthelmintics
    • 8.6.2. Ectoparasiticides
  • 8.7. Vaccines
    • 8.7.1. Inactivated Vaccines
    • 8.7.2. Live Attenuated Vaccines
    • 8.7.3. Subunit Vaccines

9. Animal Pharmaceuticals Market, by Species

  • 9.1. Introduction
  • 9.2. Aquatic Animals
  • 9.3. Birds
  • 9.4. Companion Animals
    • 9.4.1. Cats
    • 9.4.2. Dogs
    • 9.4.3. Horses
  • 9.5. Livestock Animals
    • 9.5.1. Cattle
    • 9.5.2. Poultry
    • 9.5.3. Sheep & Goats
    • 9.5.4. Swine
  • 9.6. Wild Animals

10. Animal Pharmaceuticals Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Liquid solutions
    • 10.2.3. Powders
    • 10.2.4. Tablets
  • 10.3. Parenteral
  • 10.4. Topical
    • 10.4.1. Creams
    • 10.4.2. Ointments
    • 10.4.3. Sprays

11. Animal Pharmaceuticals Market, by Disease Type

  • 11.1. Introduction
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Fungal Infections
    • 11.2.3. Parasitic Infestations
    • 11.2.4. Viral Infections
  • 11.3. Non-Infectious Diseases
    • 11.3.1. Inflammatory Diseases
    • 11.3.2. Metabolic Disorders
    • 11.3.3. Nutritional Deficiencies
    • 11.3.4. Reproductive Disorders

12. Animal Pharmaceuticals Market, by End User

  • 12.1. Introduction
  • 12.2. Government & Public Health Organizations
  • 12.3. Livestock Farms & Poultry Farms
  • 12.4. Pet Owners
  • 12.5. Research Institutions
  • 12.6. Veterinary Clinics & Hospitals

13. Animal Pharmaceuticals Market, by Distribution Channels

  • 13.1. Introduction
  • 13.2. Offline Pharmacies
  • 13.3. Online Pharmacies

14. Americas Animal Pharmaceuticals Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Animal Pharmaceuticals Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Animal Pharmaceuticals Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Aurora Pharmaceutical, Inc.
    • 17.3.2. Biogenesis Bago S.A.
    • 17.3.3. Biovac Ltd.
    • 17.3.4. Boehringer Ingelheim International GmbH
    • 17.3.5. Ceva Sante Animale
    • 17.3.6. Chanelle Pharma
    • 17.3.7. China Animal Husbandry Industry Co., Ltd.
    • 17.3.8. Dechra Pharmaceuticals PLC
    • 17.3.9. ECO Animal Health Group PLC
    • 17.3.10. Elanco Animal Health Incorporated
    • 17.3.11. Hester Biosciences Limited
    • 17.3.12. Huvepharma, Inc.
    • 17.3.13. Indian Immunologicals Ltd.
    • 17.3.14. Intas Pharmaceuticals Ltd.
    • 17.3.15. Laboratorio Drag Pharma Chile Invetec S.A.
    • 17.3.16. Merck & Co., Inc.
    • 17.3.17. Neogen Corporation
    • 17.3.18. Nippon Zenyaku Kogyo Co., Ltd.
    • 17.3.19. Norbrook Group
    • 17.3.20. Orion Corporation
    • 17.3.21. PetIQ, LLC
    • 17.3.22. Phibro Animal Health Corporation
    • 17.3.23. Teknofarma S.r.l.
    • 17.3.24. Veterinary Pharmaceutical Solutions
    • 17.3.25. Vetoquinol Group
    • 17.3.26. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
    • 17.3.27. Virbac S.A.
    • 17.3.28. Zendal Group
    • 17.3.29. Zoetis Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ANIMAL PHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ANIMAL PHARMACEUTICALS MARKET: RESEARCHAI
  • FIGURE 28. ANIMAL PHARMACEUTICALS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ANIMAL PHARMACEUTICALS MARKET: RESEARCHCONTACTS
  • FIGURE 30. ANIMAL PHARMACEUTICALS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ANIMAL PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 213. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 231. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 233. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 243. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 246. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 247. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 263. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 267. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 269. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 273. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 277. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 279. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 281. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 283. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 285. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 287. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 289. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 291. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 293. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 296. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 297. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 299. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 301. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025-2030 (USD MILLION)
  • TABLE 303. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 306. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
  • TABLE 307. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 308. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2030 (USD MILLION)
  • TABLE 309. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 310. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 311. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 312. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025-2030 (USD MILLION)
  • TABLE 313. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 314. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 315. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 316. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2030 (USD MILLION)
  • TABLE 317. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 319. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 320. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
  • TABLE 321. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 322. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
  • TABLE 323. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. ARGENTINA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)

TABL